Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Product Highlight - Fluarix Tetra

30 Nov 2017

Fluarex Tetra - Inactivated quadrivalent influenza vaccine (split virion) vaccine (inj) 0.5 mL - GlaxoSmithKline

Flu vaccines help protect millions, but do you know there is a coverage gap?1
Choose Fluarix Tetra for your patients

  • The gap in B strain coverage from TIVs* can leave your patients unprotected.2,3,4,5
  • QIVs* can help to close the B strain coverage gap6,7
  • Fluarix Tetra is a QIV* which is generally well tolerated, is easy to administer, helps to increase protection against influenza B over TIVs*, closes the coverage gap to protect your patients and has robust data in high risk patients group6,8

*TIV: Trivalent Influenza Vaccine,QIV: Quadrivalent Influenza Vaccine

References:
1. United States Centers for Disease Control and Prevention. Quadrivalent Influenza Vaccine. Available at: https://www.cdc.gov/flu/protect/vaccine/quadrivalent.htm. Accessed on:3March 2017
2. Ambrose CS, Levin MJ. The rationale for quadrivalent infuenza vaccines Hum Vaccin Immunother 2012;8: 81-88
3. Jumat MR, et al. Genetic characterisation of in_uenza B viruses detected in Singapore, 2004 to 2009 BMC Res Notes 2014;7: 863
4. Belshe RB. The need for quadrivalent vaccine against seasonal influenza Vaccine 2010;28: D45–D53 5. Reed C, et al. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine Vaccine 2012;30: 1993-1998
6. GSK. Fluarix Tetra Quadrivalent influenza vaccine (split virion, inactivated). (2017).
7. Domachowske JB, Pankow-Culot H, Bautista M et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3–17 years. J Infect Dis. 2013; 207: 1878–1887.
8. Kieninger D, Sheldon E, Lin W, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged 18 years. BMC Infectious Diseases 2013; 13:343.

Further information is available in section 12b, New in This Issue and mims.com.
Full prescribing information is available upon request.                        

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]